These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 12571855

  • 1. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ.
    Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
    [Abstract] [Full Text] [Related]

  • 2. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [Abstract] [Full Text] [Related]

  • 3. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [Abstract] [Full Text] [Related]

  • 4. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [Abstract] [Full Text] [Related]

  • 5. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [Abstract] [Full Text] [Related]

  • 6. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.
    Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I.
    Arthritis Rheum; 2007 Sep; 56(9):3044-56. PubMed ID: 17763423
    [Abstract] [Full Text] [Related]

  • 7. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.
    Rheumatology (Oxford); 2005 Feb 15; 44(2):176-82. PubMed ID: 15494350
    [Abstract] [Full Text] [Related]

  • 10. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
    Ann Rheum Dis; 2008 Jul 15; 67(7):1011-6. PubMed ID: 17962238
    [Abstract] [Full Text] [Related]

  • 11. Low-binding alleles of Fcgamma receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients.
    Zuñiga R, Ng S, Peterson MG, Reveille JD, Baethge BA, Alarcón GS, Salmon JE.
    Arthritis Rheum; 2001 Feb 15; 44(2):361-7. PubMed ID: 11229467
    [Abstract] [Full Text] [Related]

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG, Jones RB, Burns SM, Jayne DR.
    Arthritis Rheum; 2006 Sep 15; 54(9):2970-82. PubMed ID: 16947528
    [Abstract] [Full Text] [Related]

  • 13. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.
    Cancer Res; 2004 Jul 01; 64(13):4664-9. PubMed ID: 15231679
    [Abstract] [Full Text] [Related]

  • 14. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes.
    Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, Sluiter WJ, Limburg PC, Derksen RH, van de Winkel JG, Kallenberg CG.
    Arthritis Rheum; 2000 Dec 01; 43(12):2793-800. PubMed ID: 11145038
    [Abstract] [Full Text] [Related]

  • 15. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May 01; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 16. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb 01; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

  • 17. An open study of B lymphocyte depletion in systemic lupus erythematosus.
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.
    Arthritis Rheum; 2002 Oct 01; 46(10):2673-7. PubMed ID: 12384926
    [Abstract] [Full Text] [Related]

  • 18. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B.
    Br J Haematol; 2002 Feb 01; 116(2):465-7. PubMed ID: 11841453
    [Abstract] [Full Text] [Related]

  • 19. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M.
    Rheumatology (Oxford); 2008 Jun 01; 47(6):821-7. PubMed ID: 18397955
    [Abstract] [Full Text] [Related]

  • 20. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
    Arthritis Rheum; 2009 Apr 15; 61(4):482-7. PubMed ID: 19333973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.